Back to the future: where are we taking lentiviral vector manufacturing?

Cell Gene Therapy Insights 2018; 4(11), 1137-1150.


Published: 18 December 2018
Expert Insight
Hanna P Lesch

From more than 200 clinical trials involving lentiviral vectors, only a handful of products have reached marketing approval. One reason for this may be the technical bottleneck in large-scale lentiviral vector manufacturing. Today there are several upstream and downstream technology solutions, which claim to support clinical manufacturing at large scale. These still have several limitations, such as a complex production methodology and the relatively high cost of the goods. The fragile nature of the vector further causes its own challenges. No one knows yet where the future will take us. This insight covers an overview of the current technology and discusses the possible future solutions for lentivirus manufacturing.